Integration of Automated Insulin Delivery System with One-Year Continuous Glucose Monitoring by Sequel Med Tech and Senseonics
Sequel's twiist AID System Integrates with Senseonics' Eversense 365 CGM for Improved Diabetes Management
A significant advancement in diabetes care has been made with the integration of Sequel's twiist Automated Insulin Delivery (AID) System and Senseonics' Eversense 365 Continuous Glucose Monitor (CGM). The official compatibility between the two was launched in Q3 2025, marking a first for the AID system to integrate with the Eversense 365 CGM.
The partnership between Sequel and Senseonics offers people with type 1 diabetes the ability to use Sequel’s twiist system seamlessly with the Eversense 365 CGM. This combination of long-duration CGM technology with state-of-the-art insulin delivery aims to improve glucose control and convenience.
The Eversense 365 CGM received FDA iCGM clearance in September 2024, providing a solid regulatory foundation for its integration. Sequel’s twiist system is compatible with both the Senseonics Eversense 365 and Abbott's FreeStyle Libre 3 Plus sensors, broadening user options.
Senseonics has seen strong growth with the Eversense 365, increasing their global patient base by 56% to around 6,000 by the end of 2024. The expanded CGM compatibility between Eversense and twiist offers greater personalization, more choice, and the potential for improved outcomes for people living with diabetes.
Sequel's CEO, Alan Lotvin, stated that the company is committed to investing in innovations that empower people with diabetes. Senseonics' CEO, Tim Goodnow, echoed this sentiment, stating that the collaboration with Sequel marks a significant step forward in transforming diabetes care.
The integrated system will be the first AID system compatible with Senseonics' Eversense 365, the world’s first one-year CGM system. The collaboration between the two companies is united by a shared commitment to simplifying diabetes management and improving quality of life.
The integration of Eversense and twiist is expected to be available in the third quarter of this year. This newly launched, FDA-backed diabetes management solution represents a significant advancement in combining sensor and insulin delivery technologies for improved patient outcomes.
- The integration of Sequel's twiist Automated Insulin Delivery (AID) System and Senseonics' Eversense 365 Continuous Glucose Monitor (CGM) potentially leads to improved management of chronic diseases like type-2 diabetes by enhancing glucose control and convenience.
- The collaboration between Sequel and Senseonics focuses on health-and-wellness, particularly in the area of medical-conditions, as they aim to provide personalized solutions that broaden user options, including the use of Sequel’s twiist system with the Eversense 365 CGM.
- Nutrition plays a crucial role in managing diabetes, and the integration of Eversense and twiist offers the potential for improved outcomes for people living with diabetes, as it represents a significant advancement in combining sensor and insulin delivery technologies for improved patient outcomes.
